Asthma is a phenotypically heterogeneous chronic disease of the airways, characterized by
either predominant eosinophilic or neutrophilic, or even mixed eosinophilic/neutrophilic …

Airway smooth muscle (ASM) plays a key role in bronchomotor tone, as well as in structural
remodeling of the bronchial wall. Therefore, ASM contraction and proliferation significantly …

Asthma is a very frequent chronic airway disease that includes many different clinical
phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often …

Since December 2019, coronavirus disease 2019 (COVID-19) pandemic has spread from
China all over the world and many COVID-19 outbreaks have been reported in long-term care …

Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been
recently approved as an add-on biological treatment for severe eosinophilic asthma, by both …

Background Having been approved for biological treatment of atopic dermatitis, dupilumab
has also been recently licensed as add-on therapy for severe asthma and nasal polyposis. …

Background The efficacy of dupilumab as biological treatment of severe asthma and chronic
rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the …

Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is
nowadays available in many countries for add-on biological therapy of severe eosinophilic …

Benralizumab is a humanized monoclonal antibody which binds to the α subunit of the
interleukin-5 (IL-5) receptor and to the FcγRIIIa receptor expressed by natural killer cells, thus …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment
of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, …